Hologic (NASDAQ:HOLX) Receives Coverage Optimism Score of 0.09

News articles about Hologic (NASDAQ:HOLX) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hologic earned a news impact score of 0.09 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.4494386611339 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Hologic (NASDAQ HOLX) opened at 38.20 on Friday. Hologic has a 12 month low of $35.15 and a 12 month high of $46.80. The stock’s 50 day moving average price is $43.73 and its 200-day moving average price is $42.89. The firm has a market cap of $10.71 billion, a P/E ratio of 14.23 and a beta of 0.90.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The business’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the company posted $0.51 earnings per share. Equities research analysts anticipate that Hologic will post $2.01 earnings per share for the current fiscal year.

HOLX has been the topic of several research reports. Zacks Investment Research cut Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Royal Bank Of Canada cut their price objective on Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 3rd. Deutsche Bank AG dropped their price target on Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Stifel Nicolaus increased their price target on Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, May 11th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $51.00 price target on shares of Hologic in a research report on Friday, July 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the stock. Hologic presently has a consensus rating of “Buy” and a consensus price target of $48.64.

ILLEGAL ACTIVITY WARNING: “Hologic (NASDAQ:HOLX) Receives Coverage Optimism Score of 0.09” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/08/12/hologic-nasdaqholx-getting-somewhat-favorable-news-coverage-accern-reports-updated-updated-updated.html.

In other Hologic news, insider Peter J. Valenti III sold 10,005 shares of the firm’s stock in a transaction on Tuesday, May 30th. The shares were sold at an average price of $43.44, for a total value of $434,617.20. Following the completion of the sale, the insider now directly owns 20,994 shares in the company, valued at $911,979.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elaine Ullian sold 8,849 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $45.28, for a total transaction of $400,682.72. Following the completion of the sale, the director now owns 23,810 shares of the company’s stock, valued at $1,078,116.80. The disclosure for this sale can be found here. Insiders sold 60,627 shares of company stock valued at $2,632,911 over the last 90 days. Corporate insiders own 0.79% of the company’s stock.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit